Vancouver-based biotherapeutics company, Zymeworks Inc, has filed with Canadian and U.S. regulatory authorities for an initial public offering of its common shares. The IPO, which will give the company a listing on the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol "ZYME." Last year, Zymeworks closed one of Canada’s largest venture capital rounds, raising about $61.5 million. It was led by BDC Capital and Lumira Capital and joined by multiple other investors.